Cystinuria is a rare inherited disorder that causes a buildup of an amino acid called cystine in the urine. This can result in the formation of cystine kidney stones.
Cystine stones are often larger, harder and more frequent than other kinds of kidney stones. Due to the larger stone size, cystine stones may be more difficult to pass, often requiring surgical procedures to remove.
Stones can create blockages in the urinary tract and reduce the ability of the kidneys to eliminate waste through urine. The stones also provide sites where bacteria may cause infections.
Signs and symptoms of the condition are related to the presence of stones and may include blood in the urine, flank pain, and frequent urinary tract infections.
Cystinuria is inherited in an autosomal recessive genetic manner, meaning that a child is affected when each parent passes on one copy of the mutated gene. Symptoms tend to emerge when patients are between 10 and 30 years old . More than 80 percent of people with cystinuria develop their first stone by the age of 20. More than 25 percent will develop cystine stones by the age of 10. The disorder occurs in approximately 1 in 10,000 people in the United States.
The following organizations may be a resource for information and support for people with cystinuria and those around them:
The International Cystinuria Foundation (ICF) is a 501(c)3 non-profit organization that aims to support a growing and strong group of patients, families, professionals, and friends by providing educational and health related resources to affected individuals worldwide. The ICF also aims to promote knowledge of cystinuria within the research and medical communities in order to reduce kidney destruction, renal impairment, and subsequent health, vocational, and economic impact.
The National Kidney Foundation is the leading organization in the U.S. dedicated to the awareness, prevention and treatment of kidney disease for hundreds of thousands of healthcare professionals, millions of patients and their families, and tens of millions of Americans at risk.
The Kidney & Urology Foundation of America is a major voluntary 501c3 nonprofit health organization which, for six decades has developed and supported programs that improve the lives of those suffering from kidney and urologic diseases and those who wait for organ or tissue transplants.
The American Kidney Fund (AKF) is the nation’s leading nonprofit working on behalf of the 31 million Americans with kidney disease. AKF helps people fight kidney disease and live healthier lives by providing a complete spectrum of programs and services: prevention activities, top-rated health educational resources, and direct financial assistance enabling 1 in 5 U.S. dialysis patients to access lifesaving medical care, including dialysis and transplantation. AKF also invests in clinical research to improve outcomes for kidney patients, and fights tirelessly on Capitol Hill for legislation and policies supporting the issues that are important to kidney patients. The organization provides these critically needed services while maintaining a 4-star rating from Charity Navigator, which ranks AKF in its list of top 10 charities in the United States for excellent fiscal management. AKF spends 97 cents of every donated dollar is spent on programs that directly serve and educate patients and the public.
Global Genes is a non-profit patient advocacy organization working to eliminate the challenges of rare disease by building awareness, educating the global community, and providing critical connections and resources that equip advocates to become activists for their disease. Global Genes promotes the needs of the rare disease community under a unifying symbol of hope – the Blue Denim Genes Ribbon™. Numerous tools, resources and educational events can be found on the Global Genes website www.globalgenes.org.
The National Organization for Rare Disorders (NORD) is a unique federation of voluntary health organizations dedicated to helping people with rare "orphan" diseases and assisting the organizations that serve them. NORD is committed to the identification, treatment and cure of rare disorders through programs of education, advocacy, research and service. In the US, NORD is also the official sponsor of Rare Disease Day, an annual global observance that raises awareness of rare diseases and elevates them into the public consciousness as an important health issue that cannot be ignored.
EURORDIS is a non-governmental patient-driven alliance of more than 700 rare disease patient organisations in more than 60 countries. EURORDIS strives to build a strong pan-European community of patient organisations and people living with a rare disease, to be their voice at the European level, and - directly or indirectly - to fight against the impact of rare diseases on their lives. EURORDIS leads global efforts for Rare Disease Day and the online social platform for people living with or affected by a rare diseases RareConnect. EURORDIS represents the voice of an estimated 30 million people living with a rare disease in Europe. Follow @eurordis or see the EURORDIS Facebook page. For more information visit: www.eurordis.org.